Navigation Links
Roper Industries Announces Record Third Quarter Results
Date:10/25/2007

Diluted Earnings Per Share of $0.70; Sales Up 25%; Net Earnings up 28% to

$65 Million; Operating Cash Flow of $91 Million

SARASOTA, Fla., Oct. 25 /PRNewswire-FirstCall/ -- Roper Industries, Inc. (NYSE: ROP) reported results for the third quarter ended September 30, 2007 that again exceeded performance in any quarter in the Company's history. Diluted earnings per share (DEPS) were $0.70 compared to $0.56 in the third quarter of 2006. Net earnings were up 28% to $65 million compared to the third quarter 2006. The tax rate for the quarter was 35.0% compared to 33.8% in the third quarter 2006. Third quarter net sales were $533 million, an increase of 25% over the comparable period in the prior year. Excluding acquisitions, internal sales increased 16%, including a 2% benefit from foreign exchange. Net orders were $533 million, an increase of $97 million over the third quarter of 2006; excluding acquisitions, internal orders were up 12%.

"We continue to have exceptional internal sales and orders growth, and our recent acquisitions have performed well across the board," said Brian Jellison, Roper's Chairman, President and CEO. "The combination of this growth and our strong operating performance enabled us to increase EBITDA to a record $137 million with EBITDA margins reaching 25.8%. We are pleased to have delivered operating cash flow of $91 million, which represents 17% of net sales, and cash conversion of 140%. Despite challenges in the Imaging Segment, we achieved operating margins of 21.3%, up 80 basis points from 2006. We are pleased that Roper passed two important milestones in the quarter, with trailing twelve months (TTM) EBITDA exceeding $500 million and TTM sales exceeding $2 billion for
'/>"/>

SOURCE Roper Industries, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Proper Diet Can Counter Macular Degeneration
2. FDA issues warning for Droperidol
3. Tetanus causing toxin has therapeutic properties
4. Compounds Found In The Vegetable Broccoli Could Have Anti-Cancer Properties
5. Geriatric Patients With Chronic Kidney Disease May Not Be Treated Properly
6. The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties
7. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
8. Fruits And Vegetables Have Arthritis Risk Reducing Property
9. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
10. Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases
11. Improperly Placed And Heavy Backpacks Lead To Back Pain In School Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , Brain perfusion applic...nterprise using the Ziostation® thin-client sy...if (PRWEB) January 8, 2009 -- Ziosoft®, Inc. ...software for medical imaging , today announced th...Food and Drug Administration (FDA) for its CT brai...
(Date:1/7/2009)... , SEATTLE, Jan. 8 Ce... announced today that they received $7.5 million p...trum Pharmaceuticals, Inc. to commercialize and de..., the Company received the initial $7.5 million pa...action. The Company may earn up to an additional ...
(Date:1/7/2009)... , BOSTON The drive toward containing health ca...reducing physician productivity, impairing quality...l Deaconess Medical Center physicians suggest in a..., Citing studies in behavioral economics and psyc...D, express the fear that assigning a monetary valu...
(Date:1/7/2009)... , SAN MARCOS, Calif., Jan, 7 Natural Alternative... leading formulator, manufacturer and marketer of ...d that effective December 31, 2008 its former Pres... , , NAI also announced it completed certain amen...k. Among other changes the amendments extend the ...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Cost containment focus could have consequences for health care delivery 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2
...high cholesterol levels are more likely to develop.... Researchers studied the eating habits and choles...about five years. The children were examined by do...ol, and LDL, or bad cholesterol, measured periodic...
...e that male babies who grow slowly in their first ... results hold true regardless of the socioeconomic...w infant growth may be accompanied by hampered bra...oor growth in infancy lead to lifelong impairment ...
...solved the puzzle of why baby boys are so much big...ring pregnancy. Women carrying male embryos consum...re protein and have a higher intake of carbohydrat...cepted that on average newborn boys are heavier th...
... the frequency of hot flashes in menopausal women,...gh an independent researcher said the drug's effec...rmone replacement therapy for menopausal symptoms ...sleep problems will be looked at more closely beca...
Other Medicine News:
(Date:1/7/2009)...RNewswire/ -- Circassia Ltd, a specialty,biopharm...care, today,announced that following successful c...une(R) anti-allergy technology, the company has no...se II clinical trial in cat allergy. The,study, w...ents with confirmed,cat allergies, and all the pa...
(Date:1/6/2009)...e-USNewswire/ -- Sequella, Inc., a clinical-stage ...pidemic potential, announced today that SQ109, its...osis (TB), was the first drug approved for evaluat...o Dynport Vaccine Company LLC and Quintiles Transn...titute of Allergy and Infectious Diseases (NIAID),...
(Date:1/5/2009)...wire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI...proprietary,antibodies for the treatment of cance... an outlook on key events anticipated for the year...pdate on its research and development,programs at... 2009: Update on several preclinical BiTE antibodi...
(Date:12/27/2008)...Newswire-FirstCall/ -- Warner Chilcott Limited (Na...sidiaries and Mayne Pharma International Pty. Ltd....led lawsuits against each of Mutual Pharmaceutical...nc. ("Mylan") and Impax Laboratories, Inc. ("Impax...Jersey for infringement of Mayne,s U.S. Patent No....
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 1UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 2UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 4UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 5LA BioMed researcher says unexpected increase in cancer risk found 13475 1LA BioMed researcher says unexpected increase in cancer risk found 13475 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 1LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 3LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 4LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 5LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 6LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 7LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 8LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 9LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 10LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 11LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 12Bristol Myers Squibb Announces Dividend 3710 1
...erland, April 25, 2007 - Basilea Pharmaceutica Ltd...s showing that,patients with severe chronic hand e...oin. In two previous randomized clinical,trials, a...severe,chronic hand eczema in patients refractory ...ated that patients responsive to initial,treatment...
....--(BUSINESS WIRE)--Apr 25, 2007 - OSI,Pharmaceuti...ults,published yesterday in the Journal of Clinica... to gemcitabine chemotherapy,significantly improve... to patients with advanced pancreatic cancer. Data... Institute of Canada (NCIC),formed the basis of b...
Other Medicine Technology:Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4
STABIBAG Hydrophilic Acrylic Lens.
XL STABI Hydrophilic Acrylic Lens.
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
XL OCTO Hydrophilic Acrylic Lens.
Medicine Products: